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Abstract
Background: Obesity is caused by excessive fat or carbohydrate intake. The improvement of obesity is an
important issue, especially in Western societies. Both low-carbohydrate diet (LCD) and low-fat diet (LFD) are used to
achieve weight loss in humans. To clarify the mechanisms underlying LCD-induced weight loss, especially in early
stage, we compared the gene expression in liver, white adipose tissue (WAT) and brown adipose tissue (BAT) of a
very-low carbohydrate diet (VLCD)- and LFD-fed diet-induced obese (DIO) mice.
Methods: DIO male ddY mice were divided into high-fat diet (HFD), and isoenergetic VLCD and LFD groups. Pair-feeding
was performed in the VLCD and LFD groups. Three weeks later, the body, liver, WAT and BAT were weighed and the
serum and hepatic lipids, the mRNA expression levels in each tissue, and energy metabolism were analyzed.
Results: The caloric intake of the VLCD-fed mice was initially reduced but was subsequently restored. The total energy
intake was similar in the VLCD- and LFD-fed mice. There was a similar decrease in the BW of the VLCD- and LFD-fed mice.
The VLCD-fed mice had elevated levels of serum fibroblast growth factor 21 (FGF21) and ketone bodies, which are known
to increase energy expenditure. The browning of WAT was observed to a greater extent in the VLCD-fed mice. Moreover,
in the VLCD-fed mice, BAT activation was observed, the weight of the BAT was decreased, and the expression of
G-protein-coupled receptor 120, type 2 iodothyronine deiodinase, and FGF21 in BAT was extremely increased. Although
the energy expenditure of the VLCD- and LFD-fed mice did not differ, that of the VLCD-fed mice was sometimes higher
during the dark cycle. Hepatic TG accumulation was reduced in LFD-fed mice due to their decreased fatty acid uptake
but not in the VLCD-fed mice. The pro-inflammatory macrophage ratio was increased in the WAT of VLCD-fed mice.
Conclusions: After 3 weeks, the isoenergetic VLCD- and LFD-fed DIO mice showed similar weight loss. The
VLCD-fed mice increased serum concentration of FGF21 and ketone bodies, and marker mRNA levels of
browning in WAT, activation in BAT and hepatic lipogenesis.
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Background
The prevalence of obesity in Western societies, which is
associated with increased fat or carbohydrate consump-
tion, has increased dramatically [1–3]. The numerous
clinical consequences of obesity include nonalcoholic
fatty liver disease (NAFLD) [4], type 2 diabetes [5–8],
and coronary heart disease [9]. The increase in obesity
underlies the urgent need to test the safety and efficacy
of widely-used weight-loss diets.
The low-carbohydrate diet (LCD) has increasingly
gained attention as an alternative to the conventional
low-fat diet (LFD) achieving effective weight loss and
lowering serum triglyceride (TG) and insulin concentra-
tions [10, 11]. However, there are conflicting reports of
the weight loss and the changes in health-related bio-
markers that occur with these diets. Systematic reviews
and meta-analyses of the weight-loss effects and blood
lipid and glucose level changes that occur with these
diets have been reported. They suggested that an LCD of
up to 6 months in duration might be a feasible alterna-
tive to an LFD for achieving weight loss and reducing
the risk of cardiovascular disease; however, these effects
are controversial at 12 months [12–14]. A recent study
showed no differences at two years when overweight and
obese adults were randomly assigned to undergo LCD
and isoenergetic weight loss diets [15].
The effects of a very-low carbohydrate diet (VLCD)-
fed C57BL/6 mice (ketogenic diet) revealed that weight
loss was caused by increased energy expenditure; how-
ever, the studies compared obese HFD-fed mice with
post-weight-loss VLCD-fed mice [16, 17]. VLCD-fed
C57BL/6 mice remain lean, euglycemic, and hypoinsuli-
nemic for longer but accumulate hepatic lipids [16]. In
contrast, LCD-fed ob/ob mice exhibit persistent weight
gain in spite of normalized fasting glycemia and reduced
insulin and lipid levels [18, 19]. The analysis from the
liver obtained from the VLCD-fed diet-induced obese
(DIO) mice revealed that mRNA levels of sterol regu-
latory element-binding protein (SREBP)-1c, a transcrip-
tional factor by which de novo lipogenesis is stimulated,
and the target genes, such as fatty acid synthase (FAS),
stearoyl-CoA desaturase 1 (SCD1), were decreased com-
pared with the high-fat diet (HFD)-fed DIO mice [16].
There is no information about the expression of pero-
xisome proliferator-activated receptor (PPAR)α, a tran-
scription factor responsible for fatty acid oxidation. The
mice fed an HFD markedly increase the fatty acid intake
of the liver and cause NAFLD, due to the elevated
expression of PPARγ2 and the target genes [20]. NAFLD
can be considered as an early predictor of metabolic
disorders and type 2 diabetes; particularly in the normal-
weight Asians and Caucasians [21, 22].
VLCD-fed non-obese C57BL/6J mice were reported to
increase mRNA level of fibroblast growth factor 21
(FGF21), one of the hepatokines, in the liver rather than
normal chow-fed mice [17]. Moreover, VLCD-fed non-
obese C57BL/6J mice increased the gene expression
levels of inflammatory factors in the liver [23]. Other-
wise, these mice were reported to show a decrease on
the levels of mRNA relating to the inflammation in
white adipose tissue (WAT) [23]. WAT is an important
endocrine organ which secretes adipokines, such as
adiponectin and leptin. The expression of adiponectin in
WAT is activated during adipogenesis, but it is signifi-
cantly reduced in WAT from obese mice and humans
[24]. Leptin, the product of the ob gene, is induced in
WAT under the HFD [25]. Obesity is associated with
chronic, low-grade inflammation. In fact, the expression
of monocyte chemoattractant protein (MCP)-1 is
increased in WAT in DIO mice and MCP-1 protein is
considerd as one of the key chemokines that regulate
migration and infiltration of macrophages [26]. Recently
inducible ‘brown-like’ adipocytes, also known as ‘beige’
cells, have been reported to develop in WAT in response
to various activators. These cells express a broad gene
program that is distinct from either white or classical
brown adipose tissue (BAT) which dissipates energy to
produce heat and plays an importnant role in the regu-
lation of energy balance [27, 28]. Promoting the deve-
lopment of brown or beige adipose tissue may protect
against obesity and related metabolic features.
There are a few reports about the gene expression in
the tissue from DIO mice after VLCD feeding as follows:
liver [16, 23] and WAT [23]. Furthermore, no reports
documenting the differences in the levels of mRNA in
the liver, WAT and BAT between VLCD- and LFD- fed
DIO mice have been published.
Therefore, we aimed to investigate the gene expression
in liver, WAT, and BAT of DIO mice after isoenergetic
VLCD and LFD feeding to clarify the systemic effects
caused by VLCD feeding, especially in early stage. More-
over, we investigated the effects of these two diets on
serum chemicals and also compared energy expenditure
in similarly-weighted VLCD- and LFD-fed mice.
Methods
Animals
Six-week-old male ddY (n = 24) mice were obtained
from Japan SLC, Inc. (Hamamatsu, Japan) and fed a nor-
mal laboratory diet (CE2; This diet is a GLP-compliant,
standard rodent diet consisting mainly of vegetable
protein with a proper balance of animal protein, Clea,
Tokyo, Japan) for 1 week to stabilize metabolic condi-
tions. Mice were exposed to a 12-h light/12-h dark cycle,
and the room was maintained at a constant temperature
of 22 °C. They were individually housed and allowed free
access to experimental diets and water. Mice were cared
for in accordance with the NIH Guide for the Care and
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Use of Laboratory Animals. All animal procedures were
reviewed and approved by the National Institute of
Health and Nutrition (No. 1311).
Diets
Seven-week-old ddY mice were fed the HFD consisting
of 60 energy% (en%) fat for 8 weeks to generate DIO.
Eight mice each were subsequently assigned to one of
three groups (HFD, VLCD, and LFD, n = 8 in each
group). The diet preparations were similar to those of
our previous studies [29, 30]. Detailed compositions of
the experimental diets are listed in Table 1. The VLCD
and the LFD contained 0.4 and 70 en% carbohydrate, re-
spectively. VLCD chow was frozen once and cut up be-
fore feeding. The HFD-fed mice had ad libitum access
to food for three more weeks. A 3-week pair-feeding
study was performed, in which LFD-fed mice were fed
an equal amount of food to that which the VLCD-fed
mice consumed on the previous day. It is because the
VLCD- and LFD-fed mice decreased their food intake in
an early stage but the VLCD-fed mice showed a lower
food intake than the LFD-fed mice. The food was pro-
vided to mice every day. Food intake per day was esti-
mated by subtracting the food weight of that day from
the initial food weight of the previous day. With these
data, average energy intakes during total experimental
periods in each group of mice were calculated.
Quantitative RT-PCR
The mice were euthanized by cervical dislocation, and
the liver, epididymal WAT (eWAT), mesenteric WAT,
subcutaneous WAT (sWAT) and BAT were isolated for
RNA preparation in the morning from 3-h fasted
animals to avoid acute effects of food intake. Total RNA
isolated from the tissues was reverse transcribed with
ReverTra Ace (Toyobo Co., Ltd., Osaka, Japan) with
random hexamers. The resulting cDNA was PCR ampli-
fied in the 96-well format with SYBR Green PCR Master
Mix and a 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA). Expression levels of test
genes were normalized to those of an endogenous
control, acidic ribosomal phosphoprotein P0 (36B4). The
level of 36B4 was invariable among samples of all experi-
ments. The relative expression levels were calculated
according to the formula 2-ΔCt, where ΔCt is the differ-
ence in threshold cycle (Ct) values between the target
and 36B4 endogenous control. The primers used for
quantitative RT-PCR are listed in the previous report
[20, 27, 29, 31] and in Table 2.
Serum chemistries
The serum was obtained from the blood after standing
for 30 min on ice and centrifugation for 15 min at
3,000 rpm at 4 °C. The serum glucose, TG, total choles-
terol (TC), insulin, leptin, and adiponectin levels were
determined as described previously [29, 32]. Serum glu-
cose was measured on the Ascensia autoanalyzer (Bayer
Corp., Tokyo, Japan). Serum TG and TC were assayed
enzymatically using colorimetric kits, TG E test and
cholesterol E test (Wako Pure Chemicals, Osaka, Japan).
Serum insulin, leptin, and adiponectin were determined
by the mouse insulin ELISA kit (Morinaga, Kanagawa,
Japan), the mouse leptin ELISA kit (Morinaga), and
mouse/rat adiponectin ELISA kit (Otsuka pharmaceutical
Co, Tokyo, Japan), respectively. FGF21 was determined
using a mouse FGF-21 DuoSet ELISA kit (R&D Systems,
Inc., Minneapolis, MN). Serum ketone body levels were
determined using an Autokit Total Ketone Bodies assay
(Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Liver and feces analyses
Lipids in the liver and feces were extracted quantitatively
with an ice-cold mixture of chloroform and methanol
(2:1, v/v) by the method of Folch et al. [33]. After the
organic phase was dried, extracted TG and TC in the
liver and feces were measured as described above [32].
Liver glycogen was extracted and digested to glucose to
determine its quantity using anthrone method as de-
scribed previously [34].
Hepatic histology
Mouse livers were fixed in 4 % neutral-buffered for-
malin, embedded in paraffin, cut into sections, and
stained with Oil red O as previously described [29]. For
Oil red O staining, a stock solution of Oil Red O (0.5 g/
100 mL) in isopropanol was prepared, stored, and
protected from light.
Measurement of oxygen consumption and carbon dioxide
production
Open-circuit indirect calorimetry was performed with an
O2/CO2 metabolism measuring system for small animals
Table 1 The dietary composition of experimental diets
Component HFD VLCD LFD
g / 100 g
Safflower oil 8.4 18.3 4.0
Butter 25.2 54.8 –
Casein 26.4 8.1 20.0
α-Cornstarch 26.3 0.7 66.2
Vitamin mixture (AIN-93) 1.4 1.9 1.0
Mineral mixture (AIN-93) 4.9 6.6 3.5
Cellulose powder 7.0 9.4 5.0
L-Cystine 0.42 0.56 0.30
HFD high-fat diet, VLCD very-low carbohydrate diet, LFD low-fat diet
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(MK-5000RQ; Muromachi Kikai, Tokyo, Japan). The sys-
tem monitored oxygen consumption (VO2) and carbon
dioxide production (VCO2) at 3-min intervals and calcu-
lated the respiratory quotient (RQ) ratio (VCO2/VO2).
Spontaneous motor activity was measured using the
Supermex infrared sensor (Muromachi Kikai). Measure-
ments were performed for the dark (from 19:00 to 7:00)
or light (from 7:00 to 16:30) period under ad libitum
feeding conditions. The substrate utilization rate and en-
ergy production rate were calculated using the formula
used by Ferrannini [35] where the rate of glucose oxida-
tion (g/min) = 4.55VCO2 (L/min)-3.21VO2(L/min)-
2.87 N(mg/min), the rate of lipid oxidation (g/min) = 1.67
(VO2-VCO2)-1.92N, and the rate of energy production
(kcal/min) = 3.91VO2 + 1.10VCO2-3.34N, where N is the
rate of urinary nitrogen excretion used to estimate protein
oxidation. However, considering that only a small portion
of resting and exercise energy expenditure arises from
protein oxidation [36], the contributions of protein oxida-
tion were neglected.
Table 2 The primers used for quantitative PCR
































36B4 acidic ribosomal phosphoprotein P0, Arg arginase, BDH 3-hydroxybutyrate dehydrogenase, CD36 fatty acid translocase, D2 type 2 iodothyronine deiodinase, Elovl6
elongation of very long-chain fatty acid 6, FAS fatty acid synthase, FGF21 fibroblast growth factor 21, GPR G-protein-coupled receptor, HADH hydroxyacyl-coenzyme A
dehydrogenase, HMGCS2 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2, MCADmedium-chain acyl-CoA dehydrogenase, MCP monocyte chemoattractant protein,
Mincle the macrophage inducible C-type lectin, MR mannose receptor, NOS nitric oxide synthase, PGC peroxisome proliferator-activated receptor γ coactivator, PPAR
peroxisome proliferator-activated receptor, SCD1 stearoyl-CoA desaturase 1, SREBP sterol regulatory element-binding protein, TBX1 T-box 1 transcription factor C,
TMEM26 transmembrane protein 26, UCP uncoupling protein
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Statistical analysis
A one-way analysis of variance was performed (StatView
Version 5.0, Abacus Concepts, Inc., Berkeley, CA) for
the inter-group comparisons. Statistically significant var-
iables were compared by Fisher’s protected least signifi-
cance test. Statistical significance was set at P < 0.05.
Results
Food intake, weight loss, and body composition in the
VLCD and LFD groups
The ddY mice feeding HFD for 8 weeks became obese
(58.9 ± 0.6 g, n = 24). Thereafter, they were divided into 3
groups, HFD, VLCD and LFD group (n = 8 in each group).
For the first week, the energy intake of the VLCD-fed mice
was spontaneously reduced by 28 % (P < 0.001). However,
their food intake gradually increased and was not reduced
in the final week (Fig. 1a). The total energy intake was
similar in the VLCD- and LFD-fed mice (Fig. 1b). The
body weights (BWs) of the HFD-fed mice increased to
106 % at 3 weeks. There was a significant decrease in the
BWs of the VLCD- and LFD-fed mice (14 and 11 %,
respectively, P < 0.001 for both groups vs HFD); the differ-
ence in the rate of decrease was non-significant (Fig. 1c
and d). The weights of the liver (HFD, 2.710 ± 0.153 g;
VLCD, 1.989 ± 0.147 g; LFD, 2.040 ± 0.064 g; HFD vs
VLCD, P < 0.001; HFD vs LFD, P < 0.001), eWAT (HFD,
2.665 ± 0.405 g; VLCD, 1.864 ± 0.125 g; LFD, 1.511 ±
0.222 g; HFD vs VLCD, P < 0.05; HFD vs LFD, P < 0.01),
retroperitoneal WAT (HFD, 0.699 ± 0.072 g; VLCD, 0.439
± 0.024 g; LFD, 0.388 ± 0.046 g; HFD vs VLCD, P < 0.01;
HFD vs LFD, P < 0.001), mesenteric WAT (HFD, 1.302 ±
0.154 g; VLCD, 0.573 ± 0.035 g; LFD, 0.698 ± 0.080 g; HFD
vs VLCD, P < 0.001; HFD vs LFD, P < 0.01), and sWAT
(HFD, 2.231 ± 0.171 g; VLCD, 1.045 ± 0.094 g; LFD,
0.979 ± 0.153 g; HFD vs VLCD, P < 0.001; HFD vs LFD,
P < 0.001) were significantly lower in the VLCD- and
LFD-fed mice than in the HFD-fed mice (Fig. 1e-i). The
BAT weight was significantly lower in the VLCD-fed mice
than in the HFD- and LFD-fed mice (HFD, 0.359 ±
0.049 g; VLCD, 0.179 ± 0.019 g; LFD, 0.303 ± 0.029 g; HFD
vs VLCD, P < 0.01; VLCD vs LFD, P < 0.05; Fig. 1j). The
weights of the gastrocnemius and quadriceps were similar
in all groups (Fig. 1k and l).
Hepatic analyses
Although there was a dramatic decrease in the BWs of
the mice in the VLCD and LFD groups at 3 weeks
(HFD, 63.088 ± 1.080 g; VLCD, 51.925 ± 1.107 g; LFD,
52.638 ± 1.686 g; HFD vs VLCD, P < 0.001; HFD vs
LFD, P < 0.001; Fig. 1d), the effects of these diets on
NAFLD were different. The liver TG content of the
VLCD-fed mice was equal to that in the HFD-fed mice,
indicating a same increase compared to the HFD-fed mice
at 3 weeks (Fig. 2a). In contrast, hepatic TG and TC
accumulation were markedly decreased in the LFD-fed
mice compared to the HFD- fed mice (HFD vs LFD, P <
0.001; VLCD vs LFD, P < 0.001 for TG; HFD vs LFD, P <
0.05 for TC; Fig. 2a and b). The liver glycogen content of
the VLCD-fed mice was almost the same as that of the
HFD- and LFD-fed mice, indicating that glycogen synthe-
sis was sufficient despite the lack of carbohydrates in the
diet (Fig. 2c). Oil red O staining confirmed hepatic TG ac-
cumulation in both the HFD- and VLCD-fed mice but not
in LFD-fed mice (Fig. 2d-f).
Serum and feces analyses
The serum glucose and TG concentrations of the HFD-,
VLCD- and LFD-fed mice were the same (Fig. 3a and b).
The serum TC concentration was lowest in the VLCD-
fed mice, while that in the LFD-fed mice was also lower
than in the HFD-fed mice (HFD, 5.11 ± 0.25 mmol/L;
VLCD, 3.05 ± 0.03 mmol/L; LFD, 4.15 ± 0.24 mmol/L;
HFD vs VLCD, P < 0.001; HFD vs LFD, P < 0.05; VLCD
vs LFD, P < 0.01; Fig. 3c). The serum insulin and leptin
concentrations were significantly decreased in the VLCD-
and LFD-fed mice (insulin; HFD, 1.39 ± 0.25 pmol/L;
VLCD, 0.27 ± 0.03 pmol/L; LFD, 0.52 ± 0.10 pmol/L; HFD
vs VLCD, P < 0.001; HFD vs LFD, P < 0.001; leptin;
HFD, 36.84 ± 5.99 ng/mL; VLCD, 5.39 ± 1.60 ng/mL;
LFD, 8.37 ± 1.73 ng/mL; HFD vs VLCD, P < 0.001; HFD
vs LFD, P < 0.001; Fig. 3d and Fig. 3e). The serum
β-hydroxybutyrate (major circulating ketone) level was
significantly elevated in the VLCD-fed mice compared to
the HFD- and LFD-fed mice (HFD, 414 ± 24 μmol/L;
VLCD, 694 ± 34 μmol/L; LFD, 436 ± 32 μmol/L; HFD vs
VLCD, P < 0.001; VLCD vs LFD, P < 0.001; Fig. 3f). There
was no difference in the serum adiponectin concentration
(Fig. 3g). The serum FGF21 concentration was signifi-
cantly increased in the VLCD-fed mice (HFD, 90.1 ±
29.1 pg/mL; VLCD, 245.7 ± 54.5 pg/mL; LFD, 84.7 ±
12.2 pg/mL; HFD vs VLCD, P < 0.001; VLCD vs LFD,
P < 0.001; Fig. 3h). The fecal TG content was significantly
increased in the VLCD-fed mice (HFD, 4.41 ± 1.27 mg/g;
VLCD, 24.11 ± 4.88 mg/g; LFD, 1.18 ± 0.21 mg/g; HFD vs
VLCD, P < 0.001; VLCD vs LFD, P < 0.001; Fig. 3i). It is es-
timated that 0.3, 1.1, and 0.4 % of the ingested fat was ex-
creted as feces in the HFD-, VLCD-, and LFD-fed mice,
respectively.
Hepatic mRNA expression in HFD-, VLCD- and LFD-fed
mice
The decrease in the liver TG content of the LFD-fed
mice, led us to investigate mRNA expression in the liver
of HFD-, VLCD- and LFD-fed mice. We previously
reported that an HFD increased PPARγ2 mRNA expres-
sion in mice [20]. There was a decrease in the mRNA
levels of PPARγ1, γ2, and fatty acid translocase (CD36: a
target gene of PPARγ) in the LFD-fed mice; however,
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the VLCD-fed mice showed the highest PPARγ2 level
(PPARγ1; HFD, 100 ± 28; VLCD, 99 ± 30; LFD, 38 ±
12; HFD vs LFD, P < 0.05; VLCD vs LFD, P < 0.05;
PPARγ2; HFD, 100 ± 65; VLCD, 224 ± 53; LFD, 14 ± 5;
VLCD vs LFD, P < 0.01; CD36; HFD, 100 ± 16; VLCD,
96 ± 21; LFD, 48 ± 8; HFD vs LFD, P < 0.05; VLCD vs
LFD, P < 0.05; Fig. 4a). On the other hand, there was a
significant decrease in the expression of SREBP-1c in the
VLCD-fed mice compared to the HFD- and LFD-fed mice
(HFD, 100 ± 12; VLCD, 45 ± 7; LFD, 78 ± 11; HFD vs
VLCD, P < 0.001; VLCD vs LFD, P < 0.05; Fig. 4b). SREBP-
1c activation increases the expression of lipogenic genes,
such as FAS, SCD1, and elongation of very long-chain fatty
acid 6 (Elovl6) [20]. The levels of these mRNAs were also
decreased in VLCD-fed mice (FAS; HFD, 100 ± 19; VLCD,
42 ± 4; LFD, 88 ± 17; HFD vs VLCD, P < 0.01; VLCD vs
LFD, P < 0.05; SCD1; HFD, 100.0 ± 21.9; VLCD, 0.4 ± 0.1;
LFD, 202.4 ± 24.4; HFD vs VLCD, P < 0.01; HFD vs
LFD, P < 0.001; VLCD vs LFD, P < 0.001; Elovl6; HFD,
100 ± 16; VLCD, 46 ± 3; LFD, 128 ± 23; HFD vs VLCD,
P < 0.05; VLCD vs LFD, P < 0.01; Fig. 4b). There were
no differences in the expression of PPARα, of the diet-
ary groups (Fig. 4c). However, the mRNA level of the
medium-chain acyl-CoA dehydrogenase (MCAD) was
Fig. 1 Daily and total energy intake, BW change, and body and tissue weights. (a) Daily energy intake. Food intake was measured daily during
the study and weekly averages were calculated. (b) Total energy intake. (c) BW change over 3 weeks. The weights of the body (d), liver (e),
epididymal (f), retroperitoneal (g), mesenteric (h), and subcutaneous WAT (i), BAT (j), gastrocnemius (k), and quadriceps (l). HFD, high-fat diet;
VLCD, very-low carbohydrate diet; LFD, low-fat diet. Values are the mean ± SEM (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001
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significantly lower in the LFD-fed mice than in the
other groups (HFD, 100 ± 8; VLCD, 120 ± 11; LFD, 60
± 8; HFD vs LFD, P < 0.01; VLCD vs LFD, P < 0.001;
Fig. 4c). The uncoupling protein (UCP)2 level was
significantly increased in the VLCD-fed mice (HFD,
100 ± 13; VLCD, 145 ± 14; LFD, 97 ± 11; HFD vs
VLCD, P < 0.05; VLCD vs LFD, P < 0.05; Fig. 4c). The
FGF21 mRNA level was significantly increased in the
VLCD-fed mice (HFD, 100 ± 27; VLCD, 225 ± 54;
LFD, 101 ± 21; HFD vs VLCD, P < 0.05; VLCD vs
LFD, P < 0.05; Fig. 4c), in accordance with the increase
in the serum FGF21 concentration. As expected from
the increase of serum ketone bodies in the VLCD-fed
mice, the mRNA levels of 3-hydroxybutyrate dehydro-
genase (BDH), hydroxyacyl-coenzyme A dehydrogenase
(HADH) and 3-hydroxy-3-methylglutaryl-coenzyme A
synthase 2 (HMGCS2), which are responsible for
ketone metabolism, were increased in these mice (BDH;
HFD, 100 ± 8; VLCD, 112 ± 9; LFD, 76 ± 4; HFD vs LFD,
P < 0.05; VLCD vs LFD, P < 0.01; HADH; HFD 100 ± 10;
VLCD, 129 ± 9; LFD, 92 ± 5; HFD vs VLCD, P < 0.05;
VLCD vs LFD, P < 0.01; HMGCS2; HFD, 100 ± 6;
VLCD, 124 ± 14; LFD, 81 ± 5; VLCD vs LFD, P < 0.01;
Fig. 4d).
Gene expression in the WAT of HFD-, VLCD- and LFD-fed
mice
The body and WAT weights were significantly decreased
in the VLCD- and LFD-fed mice. We therefore exam-
ined mRNA expression in the eWAT and sWAT. As
shown in Fig. 5a, there were no significant differences in
the PPARγ1, γ2 and CD36 levels in the eWAT of the
three groups. However, these mRNAs were significantly
decreased in the sWAT of LFD-fed mice, PPARγ1 and
CD36 mRNAs were significantly decreased in the VLCD-
fed mice. Adipokines, such as adiponectin and leptin, are
secreted from WAT. There were no significant differences
among the groups in the adiponectin mRNA levels in the
eWAT (Fig. 5b). Leptin expression in the eWAT and
sWAT was significantly lower in the VLCD- and LFD-fed
mice than in the HFD-fed mice in accordance with the de-
crease in serum leptin concentration (eWAT; HFD, 100 ±
24; VLCD, 41 ± 13; LFD, 60 ± 15; HFD vs VLCD, P < 0.05;
HFD vs LFD, P < 0.05; sWAT; HFD, 100 ± 28; VLCD,
10 ± 3; LFD, 6 ± 2; HFD vs VLCD, P < 0.01; HFD vs
LFD, P < 0.001; Fig. 5b). The mRNA levels of MCP-1,
one of the key chemokines that regulate migration and in-
filtration of macrophages, was significantly decreased in
all WAT types in the VLCD- and LFD-fed mice (eWAT;
Fig. 2 The hepatic analyses. (a) Liver TG, (b) liver TC, (c) liver glycogen content, and Oil red O staining of liver sections from mice fed (d) HFD, (e)
VLCD, and (f) LFD. HFD, high-fat diet; VLCD, very-low carbohydrate diet; LFD, low-fat diet. Values are the mean ± SEM (n = 8). *P < 0.05, ***P < 0.001
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HFD, 100 ± 21; VLCD, 27 ± 5; LFD, 37 ± 14; HFD vs
VLCD, P < 0.01; HFD vs LFD, P < 0.01; sWAT; HFD, 100
± 20; VLCD, 30 ± 8; LFD, 12 ± 2; HFD vs VLCD, P < 0.001;
HFD vs LFD, P < 0.001; Fig. 5b). As expected from the de-
creased MCP-1 mRNA levels, the CD68 and F4/80
(macrophage markers) mRNA levels were decreased in
the eWAT and sWAT of the VLCD- and LFD-fed mice
(CD68 in eWAT; HFD, 100 ± 18; VLCD, 42 ± 8; LFD, 64 ±
20; HFD vs VLCD, P < 0.01; HFD vs LFD, P < 0.05; CD68
in sWAT; HFD, 100 ± 22; VLCD, 22 ± 4; LFD, 19 ± 3; HFD
vs VLCD, P < 0.001; HFD vs LFD, P < 0.001; F4/80 in
eWAT; HFD, 100 ± 12; VLCD, 46 ± 6; LFD, 53 ± 12; HFD
vs VLCD, P < 0.01; HFD vs LFD, P < 0.01; F4/80 in sWAT;
HFD, 100 ± 22; VLCD, 23 ± 7; LFD, 16 ± 5; HFD vs VLCD,
P < 0.001; HFD vs LFD, P < 0.001; Fig. 5c). We next inves-
tigated the expression of pro-inflammatory M1 macro-
phage markers (nitric oxide synthase [NOS]2 and Mincle)
and anti-inflammatory M2 macrophage markers (arginase
[Arg]1 and mannose receptor [MR]) . NOS2 was in-
creased in sWAT in the VLCD-fed mice (HFD, 100 ± 15;
VLCD, 239 ± 78; LFD, 39 ± 4; HFD vs VLCD, P < 0.05;
VLCD vs LFD, P < 0.01; Fig. 5d). The mRNA level of
Mincle, the macrophage inducible C-type lectin, was in-
creased in eWAT and sWAT in the VLCD-fed mice
(eWAT; HFD, 100 ± 14; VLCD, 186 ± 27; LFD, 116 ± 26;
HFD vs VLCD, P < 0.05; sWAT; HFD, 100 ± 27; VLCD,
141 ± 20; LFD, 101 ± 10; HFD vs VLCD, P < 0.05; VLCD
vs LFD, P < 0.05; Fig. 5d). The expressions of Arg1 and
MR were decreased in the sWAT of the LFD-fed mice
(Arg1 in sWAT; HFD, 100 ± 28; VLCD, 12 ± 4; LFD, 30 ±
18; HFD vs VLCD, P < 0.05; HFD vs LFD, P < 0.05; MR in
sWAT; HFD, 100 ± 21; VLCD, 68 ± 22; LFD, 33 ± 14; HFD
vs LFD, P < 0.05; Fig. 5d). As for VLCD-fed mice, only the
Arg1 mRNA levels were decreased in eWAT and sWAT
(Arg1 in eWAT; HFD, 100 ± 31; VLCD, 20 ± 4; LFD, 56 ±
14; HFD vs VLCD, P < 0.01; Fig. 5d).
Beige/browning cells express UCP1 and a broad gene
program that is distinct from either white or classical
brown adipocytes [27]. Hence, we investigated the
expression of UCP1 and other beige/browning markers.
Increased UCP1 and PPARα mRNA levels were observed
in the eWAT of VLCD-fed mice, while only PPARα was
increased in LFD-fed mice (PPARα in eWAT; HFD,
100 ± 17; VLCD, 291 ± 45; LFD, 235 ± 58; HFD vs
Fig. 3 The serum and feces analyses. (a) serum glucose, (b) serum TG, (c) serum TC, (d) serum insulin, (e) serum leptin, (f) serum β-
hydroxybutyrate, (g) serum adiponectin, (h) serum FGF21 concentration, (i) feces TG content. HFD, high-fat diet; VLCD, very-low carbohydrate diet;
LFD, low-fat diet. Values are the mean ± SEM (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001
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VLCD, P < 0.05; HFD vs LFD, P < 0.01; UCP1 in eWAT;
HFD, 100 ± 28; VLCD, 547 ± 134; LFD, 88 ± 17; HFD vs
VLCD, P < 0.01; VLCD vs LFD, P < 0.001; Fig. 5e). In-
creased PPARα and UCP1 mRNA levels were observed in
the sWAT of VLCD-fed mice (PPARα in sWAT; HFD, 100
± 19; VLCD, 194 ± 44; LFD, 18 ± 3; HFD vs VLCD, P < 0.05;
VLCD vs LFD, P < 0.001; UCP1 in sWAT; HFD, 100 ± 28;
VLCD, 212 ± 54; LFD, 25 ± 2; HFD vs VLCD, P < 0.05;
VLCD vs LFD, P < 0.001; Fig. 5e). The increased expression
of CD137, another beige/browning marker, was observed
in the sWAT of VLCD- and LFD-fed mice (HFD, 100
± 43; VLCD, 409 ± 187; LFD, 647 ± 171; HFD vs
VLCD, P < 0.05; HFD vs LFD, P < 0.01; Fig. 5e). With
regard to the other beige/browning markers (TMEM26
and TBX1), no significant difference was observed.
Gene expression in the BAT in HFD-, VLCD- and LFD-fed
mice
In BAT, UCP1 is responsible for nonshivering thermo-
genesis [37]. The PPARα and UCP1 levels decreased in
the LFD-fed mice (PPARα; HFD, 100 ± 11; VLCD, 85 ± 9;
LFD, 68 ± 6; HFD vs LFD, P < 0.05; UCP1; 100 ± 10;
VLCD, 93 ± 6; LFD, 73 ± 10; HFD vs VLCD, P < 0.05;
Fig. 6a and b). The expression of the other UCP1 regu-
lating factor, peroxisome proliferator-activated receptor
γ coactivator (PGC)1α did not differ in the three groups
Fig. 4 The hepatic gene expression. (a) PPARγ and CD36, (b) SREBP-1c and target genes, (c) PPARα and target genes, and (d) enzymes related
to ketone body synthesis. The percentages of mRNA levels relative to those of HFD-fed mice are shown. HFD, high-fat diet; VLCD, very-low
carbohydrate diet; LFD, low-fat diet. Values are the mean ± SEM (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001
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(Fig. 6c). The mRNA level of type 2 iodothyronine deio-
dinase (D2), which converts T4 to T3, was increased in
the VLCD-fed mice (HFD, 100 ± 17; VLCD, 140 ± 42;
LFD, 56 ± 14; VLCD vs LFD, P < 0.05; Fig. 6d). Surpris-
ingly, there was an extraordinary increase in the expres-
sion of G-protein-coupled receptor (GPR)120, which is
activated by free fatty acid (FFA), in the VLCD-fed mice
(HFD, 100 ± 13; VLCD, 375 ± 102; LFD, 88 ± 25; HFD vs
VLCD, P < 0.01; VLCD vs LFD, P < 0.01; Fig. 6e). FGF21
mRNA was increased in the BAT similarly to the liver of
VLCD-fed mice (HFD, 100 ± 20; VLCD, 174 ± 45; LFD,
50 ± 24; VLCD vs LFD, P < 0.05; Fig. 6f ). There were no
significant differences in PPARγ1 expression (Fig. 6g).
PPARγ2 mRNA was significantly decreased in the
VLCD- and LFD-fed mice (HFD, 100 ± 8; VLCD, 70 ±
7; LFD, 73 ± 11; HFD vs VLCD, P < 0.05; HFD vs LFD,
P < 0.05; Fig. 6h). There were no significant differences in
CD36 expression among the three groups (Fig. 6i).
Substrate utilization in VLCD- and LFD-fed mice
Oxygen consumption was measured after 3 weeks in the
VLCD- and LFD-fed mice. The oxygen consumption of
VLCD-fed mice during the dark cycle (feeding period)
was greater than that of LFD-fed mice (P = 0.030), but
not during the light cycle (sleeping period) (Table 3).
Carbon dioxide production and the RQ decreased in the
VLCD-fed group during both the dark and light cycles
(Fig. 7a and Table 3). The activity levels were higher in
the LFD-fed mice than in VLCD-fed mice, but only in
the dark cycle (Table 3). Throughout the day, glucose
oxidation was higher in the LFD-fed mice than in the
VLCD-fed mice (P < 0.001 at all observed time, Fig. 7b
and Table 3). In contrast, lipid oxidation was higher in
the VLCD-fed mice than in the LFD-fed mice (P < 0.001
at all observed time, Fig. 7c and Table 3). The energy
production of the VLCD- and LFD-fed mice did not
differ throughout the day; however, the VLCD-fed mice
showed higher energy expenditure, especially early in
the dark cycle (Fig. 7d and Table 3).
Discussion
We herein show that the BW of DIO mice decreased as
long as their caloric intake was reduced in an early stage
of amelioration of obesity, regardless of macronutrient
Fig. 5 Gene expression in the epididymal and subcutaneous WAT. (a) PPARγ and CD36, (b) adipokines, (c) macrophage surface markers,
(d) M1 and M2 macrophage markers, and (e) browning markers. The percentages of mRNA levels relative to those of HFD-fed mice are shown. E,
Epididymal WAT; S, Subcutaneous WAT. HFD, high-fat diet; VLCD, very-low carbohydrate diet; LFD, low-fat diet. Values are the mean ± SEM (n = 8).
*P < 0.05, **P < 0.01, ***P < 0.001
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composition. Moreover, the data in this study suggest that
differences in the substrate utilization of the VLCD- and
LFD-fed mice did not affect energy production. However,
the gene expression levels in adipose and hepatic tissues
and serum chemicals were different dependently on the
macronutrient composition. Approximately 40 years ago
it was reported that two types of diets, that were identical
in caloric content (70 % carbohydrate, 20 % protein, and
10 % fat vs. 70 % fat, 20 % protein, 10 % carbohydrate)
achieved similar BW loss in obese men [38]. Since then,
the effects of altering the fat and carbohydrate content of
hypocaloric diets have been examined and thereby
reduced-calorie diets have been shown to result in clinic-
ally meaningful weight loss regardless of the macronutri-
ents that are emphasized [39–41]. However, LCDs have
increasingly gained attention as an effective means of
achieving weight loss in humans [10, 11].
In humans, an LCD usually results in a decreased caloric
intake [39, 42]. Ketone bodies (mainly β-hydroxybutyrate),
which are known to be increased by an LCD, can act both
orexigenically and anorexigenically [43]. In normo- or
hypoglycemia, β-hydroxybutyrate exerts an anorexigenic
role, thereby inducing a reduction in food intake [44, 45].
We demonstrated here that the serum β-hydroxybutyrate
concentration was elevated in VLCD-fed mice, suggesting
that the increased ketone bodies resulted in reduced
appetite and subsequent BW loss.
In the present study, NAFLD, which was caused by
the initial HFD, only improved in the LFD-fed mice -
despite the BW decrease in the VLCD-fed mice. NAFLD
is caused by an imbalance between TG synthesis and
removal in the liver [46]. This is affected by multiple
pathways, including the rate of FFA delivery to the liver,
hepatic de novo lipogenesis, FFA oxidation, and TG
secretion from the liver [46]. We demonstrated here that
the hepatic expression levels of PPARγ2 and the target
genes were higher in VLCD-fed mice than in LFD-fed
mice (Fig. 4a). In contrast, the levels of SREBP-1c and
the target genes responsible for de novo lipogenesis were
higher in the liver of LFD-fed mice (Fig. 4b). SREBP-1c
Fig. 6 Gene expression in BAT. (a) PPARα, (b) UCP1, (c) PGC1α, (d) D2, (e) GPR120, (f) FGF21, (g) PPARγ1, (h) PPARγ2, and (i) CD36. The percentages of
mRNA levels relative to those of HFD-fed mice are shown. HFD, high-fat diet; VLCD, very-low carbohydrate diet; LFD, low-fat diet. Values are the mean
± SEM (n = 8). *P < 0.05, **P < 0.01
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is required in the activation of hepatic de novo lipogen-
esis by glucose [47]. The data presented here indicate
that de novo lipogenesis was not activated in the VLCD-
fed mice because they could not utilize carbohydrates.
Moreover, serum insulin was decreased in the VLCD-
and LFD-fed mice, suggesting that insulin-stimulated de
novo lipogenesis, mediated by SREBP-1c activation, did
not act in the liver of these mice. Although the PPARα
level was unchanged in the VLCD-fed mice, MCAD and
UCP2 expression was increased in the liver, implicating
the activation of PPARα; and indicating that fatty acid
oxidation is activated due to the substantial increase in
fatty acid uptake (Fig. 4c). Taken together, these results
indicate that there was no decrease in the TG level in
the liver of VLCD-fed mice due to the high level of fatty
acid uptake in the liver and sustained high expression of
PPARγ2 and the target genes, despite decreases in BW
and serum insulin. It is now understood that NAFLD is
a precursor of nonalcoholic steatohepatitis, which pro-
gresses to cirrhosis in up to 25 % of patients [48]. More-
over, NAFLD can be considered as an early predictor of
metabolic disorders and type 2 diabetes [21, 22]. The
fact that the hepatic TG level of the VLCD-fed mice did
not decrease should be seriously considered when seek-
ing to avoid metabolic syndrome and type 2 diabetes.
WAT is an important endocrine organ which secretes
a large number of adipokines, such as leptin, which are
involved in a variety of physiological and pathological
processes [24, 25]. HFD-fed mice enlarges adipocytes,
but a decrease in WAT mass results in a decrease in the
size of these cells, which contributes to the improvement
in insulin sensitivity and adipokine secretion [49]. We
presented here that isoenergetic VLCD and LFD (regard-
less of their macronutrient composition) result in mean-
ingful reductions in BW and WAT weight in DIO mice.
Leptin is secreted by sWAT rather than visceral WAT
[50]. This is in agreement with the results of our study
as leptin mRNA was drastically decreased in the sWAT
and serum of VLCD- and LFD-fed mice. The plasma
concentration of adiponectin is inversely related to BW,
and visceral WAT is a more active producer of adipo-
nectin than sWAT [51]. However, the serum concentra-
tion of adiponectin in this study did not increase in the
VLCD- and LFD-fed mice, in spite of their weight loss.
This is attributed to a subtle increase in the expression
of adiponectin in eWAT. MCP-1 increases in the mature
adipocyte fraction of obese mice and promotes mono-
cyte infiltration into the WAT; these monocytes then
differentiate into adipose tissue macrophages (ATMs),
which secrete additional chemokines and cytokines and
exacerbate the pro-inflammatory environment [52].
There is considerable evidence that ATMs establish a
vicious cycle that aggravates inflammatory changes in
WAT, preceding or associating with ectopic lipid accu-
mulation in obese individuals [53]. There are two polar-
ized states of ATM: M1 (proinflammatory macrophages);
and M2 (anti-inflammatory macrophages) [54]. M1
macrophages enhance the production of Mincle and
proinflammatory cytokines [31], and generate NO via
iNOS (Nos2) activation [55]. M2 macrophages increase
the production of Arg1 [56], which blocks iNOS activity,
and MR leading to participate in the blockade of infla-
mmatory responses and the promotion of tissue repair
[57]. In accordance with the decrease in their fat mass,
the macrophage cell surface markers (CD68 and F4/80)
were markedly decreased in the WAT of VLCD- and
LFD-fed mice (Fig. 5c). However, the M1/M2 ratio
increased in the VLCD-fed mice. During the course of
obesity, ATMs exhibit a phenotypic switch from M2 to
M1 polarization [58]. Thus, while the condition of
VLCD-fed mice may be good at the time of evaluation,
the increased M1 macrophages in the WAT might
induce a poor metabolic state in the future.
Inducible beige/brown-like adipocytes have recently
been reported to develop in WAT in response to various
activators and act as heat-producing adipocytes [27].
Since then, several beige cells marker genes have been
proposed. Beige adipocytes have a gene expression
pattern that is distinct from WAT and BAT [59]. Beige
adipocytes, which are found in small amounts, most
frequently in the inguinal fat in rodents, express mainly
Table 3 The oxygen consumption, carbon dioxide production,
RQ ratio and spontaneous motor activity
VLCD LFD P
n 8 8
Body weight (g) 50.0 ± 0.6 51.6 ± 1.3 0.180
Dark cycle
VO2 (ml/min/kg
0.75) 23.5 ± 0.9 21.3 ± 0.3 0.030
VCO2 (ml/min/kg
0.75) 16.8 ± 0.6 20.1 ± 0.4 0.001
RQ 0.712 ± 0.001 0.944 ± 0.010 <0.001
Activity (count/min) 169 ± 10 234 ± 16 0.004
Glucose oxidation (mg/min/kg0.75) 0.78 ± 0.11 23.3 ± 1.1 <0.001
Lipid oxidation (mg/min/kg0.75) 11.3 ± 0.4 1.9 ± 0.3 <0.001
Energy production (J/min/kg0.75) 462 ± 17 441 ± 7 0.278
Light cycle
VO2 (ml/min/kg
0.75) 18.2 ± 0.8 17.2 ± 0.2 0.229
VCO2 (ml/min/kg
0.75) 13.2 ± 0.5 15.5 ± 0.1 0.001
RQ 0.726 ± 0.002 0.905 ± 0.011 <0.001
Activity (count/min) 64.8 ± 6.9 70.4 ± 5.7 0.540
Glucose oxidation (mg/min/kg0.75) 1.6 ± 0.2 15.6 ± 0.7 <0.001
Lipid oxidation (mg/min/kg0.75) 8.33 ± 0.37 2.72 ± 0.33 <0.001
Energy production (J/min/kg0.75) 358 ± 15 352 ± 4 0.738
LFD low-fat diet, RQ respiratory quotient, VLCD very-low carbohydrate diet, VO2
oxygen consumption; VCO2, carbon dioxide production
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UCP-1, CD137, TBX1, and TMEM26 [27, 60, 61].
PPARα and UCP1 were increased in the eWAT and
sWAT of the VLCD-fed mice in our study. Although the
validity of the markers is controversial, CD137 is report-
edly selective for beige adipocytes [59]. CD137 expres-
sion was extremely increased in the sWAT of both
VLCD- and LFD-fed mice. FGF21, a pleiotropic protein
involved in glucose and lipid metabolism, is mainly
secreted by the liver as a nutritionally-regulated
hormone partly induced in a PPARα-dependent manner
[62]. FGF21 was reported to promote WAT browning
[63]. Thus, increased FGF21 in the serum of VLCD-fed
Fig. 7 The respiratory quotient (RQ), glucose and lipid oxidation rates, and energy expenditure rates. (a) RQ ratio, (b) glucose oxidation rates, (c) lipid
oxidation rates, and (d) energy expenditure rates in VLCD- and LFD-fed mice. Dark and light cycles are indicated by the gray and white backgrounds,
respectively. Values are the mean ± SEM (n = 8). Statistical analysis was performed only for data from energy expenditure rates. *P < 0.05, **P < 0.01
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mice seems to induce WAT browning. The mechanism
underlying the increase in CD137 expression in the
LFD-fed mice is currently unknown, but it was reported
that the attenuation of M1 recruitment to the WAT is
beneficial to WAT browning and the improvement of
the metabolic phenotype [64]. This is the first report to
show WAT browning in DIO mice that lost weight due
to a hypocaloric diet.
Surprisingly, we observed a marked decrease in the
BAT weight of VLCD-fed mice. In a previous study, the
BAT of mice that were fed ketone ester was shown to
weigh significantly less (probably due to a decrease in
BAT fat stores) [65]. Thus, it seems that the increase in
serum ketone bodies in the VLCD-fed mice caused a
decrease in BAT weight. BAT was once thought to only
have a functional role in rodents and human infants;
however, the adult human BAT has recently been
reported to consume more glucose per gram in response
to mild cold exposure than any other tissue [66], which
indicates that BAT is responsible for non-shivering
thermogenesis. FGF21 has been reported to promote
thermogenic activity in BAT [67]. Indeed, FGF21 was
reported to reduce BW due to marked increases in total
energy expenditure [68]. Moreover, thermogenic activa-
tion has been reported to induce a significant increase in
the FGF21 mRNA levels of BAT [69]. In the present
study, FGF21 mRNA was increased in the BAT of
VLCD-fed mice (Fig. 6f ). Thus, the increase in concen-
tration of serum FGF21 and mRNA expression of FGF21
in BAT of VLCD-fed mice may demonstrate the thermo-
genic activation in part in our study. D2 is also induced
for adaptive thermogenesis in the BAT [70]. In the
present study, the BAT D2 mRNA level was highest in
the VLCD-fed mice, indicating the activation of the BAT
(Fig. 6d). Moreover, the BAT of ketone ester-fed mice
was activated and there was a 14 % increase in their total
energy expenditure [66]. These results indicate that the
BAT of VLCD-fed mice was activated through an
increase in serum ketone bodies and FGF21; however,
energy expenditure did not differ from LFD-fed mice
because of the subtle increase to clarify the differences
in this study.
We described for the first time that GPR120 mRNA
was extremely increased in the BAT of VLCD-fed mice.
GPR120 is a member of the G protein-coupled recep-
tors, which are expressed in the pancreas, intestine,
adipocytes, and macrophages and are activated by FFA,
especially medium to long-chain FFAs [71]. GPR120,
which promotes glucagon-like peptide-1 secretion in the
intestine [72], acts as a lipid sensor in adipose tissue to
sense dietary fat and control energy balance [73]. Since
BAT takes up lipolysis-mediated TG-derived FFA [74],
GPR120 is likely responsible for some metabolic state
changes in BAT, although the physiological function of
GPR120 in BAT is unknown. Further studies on function
of GPR120 in BAT are needed.
LCDs are used to treat neurological diseases such as
epilepsy. Unrestricted LCDs have adverse effects on
health-related biomarkers [75]. It was also suggested that
longer-term studies are required to determine the long-
term safety and efficacy of LCDs [41]. Taken together,
LCD might be effective to lose weight for obese subjects
for short-term because LCD decreases serum concentra-
tions of insulin and leptin. However, these effects seem
to be caused in part by the decreased appetite due to the
increased serum ketone bodies. Moreover, LCD is not
effective for amelioration of NAFLD. Therefore, emplo-
ying LCD for weight loss for a long time should be care-
fully considered.
This study demonstrates that both a VLCD and an
LFD for three weeks achieved BW loss and the improve-
ment of metabolic parameters in DIO mice but that
NAFLD was only improved by an LFD. Although the
VLCD caused WAT browning, BAT activation, and in-
crease in serum ketone bodies and FGF21, which might
have in part, led to increased energy expenditure, the
VLCD-fed mice seemed to use a “hidden power” to burn
excess fat. The temporary reduction in the food intake
of the VLCD-fed mice, the increased liver TG content
and M1/M2 ratio in WAT should be carefully consi-
dered when VLCDs are employed on a long-term basis.
Conclusion
In this study, we show here that the isoenergetic VLCD-
and LFD-fed DIO mice showed similar weight loss in an
early stage of amelioration of obesity, regardless of
macronutrient composition. We also compared and
show the differences in the levels of serum chemicals
and mRNA in liver, WAT and BAT of the VLCD- and
LCD-fed mice. The VLCD-fed mice increased serum
ketone bodies and FGF21, and mRNA levels of brown-
ing makers in WAT and GPR120, D2, and FGF21 in
BAT and these increases were considered, at least in
part, to lead to their weight loss. However, NAFLD was
only improved by LFD. Moreover, the VLCD-fed mice
increased the M1/M2 ratio in WAT. Taken together, our
study suggests that employing VLCDs for weight loss for
a long time should be carefully considered.
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